# Effects of Dapagliflozin+Saxagliptin in Addition to Metformin v/s Saxagliptin or Dapagliflozin in Patients With DM2.

> **NCT03714594** · PHASE2 · COMPLETED · sponsor: **University of Pisa** · enrollment: 48 (actual)

## Conditions studied

- Type2 Diabetes Mellitus

## Interventions

- **DRUG:** Dapagliflozin 10mg
- **DRUG:** Saxagliptin 5mg
- **DRUG:** Saxagliptin 5mg + Dapagliflozin 10 mg

## Key facts

- **NCT ID:** NCT03714594
- **Lead sponsor:** University of Pisa
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-24
- **Primary completion:** 2022-08-31
- **Final completion:** 2022-08-31
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2022-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03714594

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03714594, "Effects of Dapagliflozin+Saxagliptin in Addition to Metformin v/s Saxagliptin or Dapagliflozin in Patients With DM2.". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT03714594. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*